[A18-55] Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V

Last updated 03.12.2018

Project no.:
A18-55

Commission:
Commission awarded on 03.09.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication:

Patients with non-hyperkeratotic, non-hypertrophic actinic keratosis

Result of dossier assessment:

Actinic keratosis on face or scalp: hint of non-quantifiable (at most considerable) added benefit; on trunk or extremeties: added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

03.12.2018

AMNOG as a learning system: New study on ingenol mebutate in actinic keratosis shows added benefit

Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.